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TECHNICAL NOTE
Failure to predict cyclosporine area under the curve using a
limited sampling strategy
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Graft survival in organ transplantation has significantly im-
proved with the introduction of cyclosporin A (CsA) as a part of
the immunosuppressive protocols. However, CsA has a variety
of side effects, the primary one being renal toxicity, which may
manifest as an acute reduction in the glomerular filtration rate
(GFR) or as chronic vasculopathy and interstitial fibrosis. CsA
nephrotoxicity is normally the consequence of overtreatment
and/or drug interaction, but renal dysfunction in transplant
patients can also be due to graft rejection often resulting from
undertreatment. Major efforts have therefore been made in the
last decade to find the ideal dose of CsA that achieves the
desired immunosuppression without renal damage.
This, unfortunately, is difficult, given the difficulties of drug
monitoring. Current methods include measurement of trough
plasma or whole blood concentrations. Monitoring trough
concentrations of CsA can reveal cases of unusually rapid
drug metabolism or poor absorption, but has limited value
for assessing adequate immunosuppression or predicting pro-
tection against renal toxicity [1, 21. The limitation of trough
level monitoring may be attributed to many factors, including
a poor correlation between blood CsA concentration in the
circulation and at receptor target sites, and the intensity or
duration of drug effect due to interindividual pharmacoki-
netic differences. Determination of the area under the time-
concentration curve (AUC), calculated from the individual
pharmacokinetic profile, is more informative and allows a better
index of drug exposure [31. Thus, monitoring of AUC at clinical
steady state has been reported to be more effective than trough
level in dosage adjustment to control CsA therapy [31. How-
ever, despite a complete pharmacokinetic profile (AUC) could
provide more precise information, it is expensive and time
consuming.
Single CsA concentrations at five or six hours after dosing
have been recently reported as a suitable alternative as they
appear to correlate better with AUC values than trough levels
[4, 5]. Other studies have suggested abbreviated AUC profiles
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involving three time points as a reliable alternative to full AUC
[6, 7].
The present study was designed with the following aims: (a)
to establish the time points of CsA pharmacokinetic profile that
correlated best with AUC in renal transplant patients; and (b) to
evaluate which of the equations derived from already published
models, when applied to the present data, were predictive of
AUC.
Methods
Fifty-six patients who had received cadaveric kidney trans-
plant at the Ospedali Riuniti in Bergamo, Italy were studied.
The median dose of CsA was 3.9 mg/kg/12 hr and ranged
between 1.5 and 5.0 mg/kg/l2 hr. No dosing adjustment
had been made for at least a week before the study. The
56 pharmacokinetic profiles of the patients were based on
analyses of blood samples taken 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10,
and 12 hours after dosing. The whole-blood CsA concentra-
tions were measured using the monoclonal antibody specific
for CsA (Sandimmun radioimmunoassay kit, Sandoz Ltd,
Basel, Switzerland). On different occasions the pharmacoki-
netic profiles were determined with the same sampling schedule
in 33 of these same patients, measuring blood CsA concentra-
tions by a high-performance liquid chromatographic (HPLC)
method [8].
Statistical procedure
The AUC for each patient was calculated using the trapezoi-
dal rule. Multiple and stepwise regression analysis was done
using the AUC as the dependent variable, and the blood
concentrations grouped by time as the independent variables in
order to find the minimum number of time points that provided
a good estimate of AUC. Since other studies have made similar
analyses of the blood concentration data (determined by RIA,
specific monoclonal antibody), we tested the equations pro-
posed by these authors for their ability to predict the full AUC
obtained in our patients.
For the AUC estimate we used the equations proposed by:
(a) Johnston et al [6]:
AUC = 4.3 X [3.5 hr] + 5.5 x [8 hr] + 3.1 x [10 hr] —333, (1)
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Table 1. Correlation between individual concentrations and AUC
Time point
Coefficient of determination
RIA RIA HPLC
hr (N = 56) (N = 33) (N = 33)
0 0.726 0.729 0.809
0.5 0.346 0.322 0.351
1 0.291 0.238 0.346
2 0.383 0.298 0.668
3 0.673 0.594 0.675
4 0.601 0.618 0.731
5 0.668 0.642 0.803
6 0.624 0.672 0.827
7 0.682 0.723 0.736
8 0.733 0.704 0.648
10 0.807 0.806 0.854
12 0.830 0.810 0.911
(b) Johnston et al [61:
AUC = 7.3 x [5 hrj + 659,
(c) Grevel and Kahan [7]:
r2 = 0.8397;
AUC = 2.91 x [2hr] + 5.95 x [6hr] + ll.68[l4hr] + 153,
(d) Meyer et al [4]:
r2 = 0.963;
AUC = 2.0 x [2 hr] + 10.2 x [6 hr] + 0.2,
r2 = 0.990.
However, either because of a different sampling schedule or
different CsA administration (once or twice a day), some
modifications were needed: in equation [1] the time point at 3.5
hours was replaced with the time point at three hours or at four
hours; in equation [3] the time point at 14 hours was replaced
with the time point at 12 hours since we administered GsA
every 12 hours; equation [4] was applied as is, but it was
derived from data obtained after once-a-day CsA. Agreement
between the predicted and measured AUC was examined using
regression, and the prediction error was calculated as:
% Prediction error:
(Predicted AUC — Measured AUG)/Measured AUG x 100.
To investigate whether the derived equation depended on a
particular set of data rather than being independent from the
number of observations, we randomly selected 33 of the 56
patients and repeated the analysis on this subset of pharmaco-
kinetic profiles. The same analysis was performed on HPLC
CsA results.
Results and discussion
The correlation of AUC with the sampling time concentra-
tions is presented in Table 1. The best correlation was at 12
hours in all the instances and explained >80% of the variance in
AUC. The mean error of predicted area ranged from —63.74%
to 170.42% and from —25.50% to 99.99% for data derived from
56 and 33 pharmacokinetic profiles determined by RIA, respec-
tively, and from —29.03% to 41.33% for HPLC data.
(2)
Stepwise multiple regression analysis indicated that in the
three sets of data considered, the concentrations measured at
three time points after dosing could explain >95% of the
variance in whole blood CsA AUC, namely
AUC = 1.98 x [0.5 hr] + 2.91 x [3 hr] + 8.20 x [8 hr] + 253 (5)
r2 = 0.991
when considering 56 pharmacokinetic profiles determined by
RIA, and:
AUG=3.20x[3hr]+l.90x[Shr]+7.71 x[lOhr]+212 (6)
r2 = 0.963
when considering 33 pharmacokinetic profiles determined by
RIA, and:
AUG = 1.86 x [2 hr] + 4.04 x [6 hr] + 9.08 X [12 hr] + 127 (7)
r2 = 0.988
when considering 33 pharmacokinetic profiles determined by
HPLC. The regression of the predicted AUC over the measured
AUC using equation [5], [6] and [7] are shown in Figure 1.
(3) Despite the good coefficient of determination found between the
predicted and the actual areas, the error in AUG prediction was
unacceptable, ranging in the best case (HPLC data) from
—15.98% to 15.62%.
It should also be noted that the error in AUC prediction
(4) varied widely for each patient, depending on the equation
selected for extrapolation, as documented by the fact that some
AUC predictions were more accurate using the equation de-
rived from 33 patients than from 56 patients. These findings
challenge the notion that the larger the number of pharmaco-
kinetic profiles employed to derive an equation the more
accurate is the in AUC prediction.
Moreover, these data demonstrate that the time points which
best correlated with measured AUG also varied with the set of
data, indicating that the equation used to predict AUG depends
closely on the data selected and is not generally applicable.
Other investigators have previously addressed the question
whether the abbreviated kinetic profiles can be used to predict
AUC in patients on GsA [4—7]. A good predictive value was
observed by some models that used three [6, 7] or even one time
point [4—6]. However, applying the above models to our data,
we found a very poor correlation with the actual AUG with
major error ranges. Indeed, equation 1 could explain 82% to
93% of the variance in AUG but the associated error was
unacceptable (range —61.96% to 57.69%). Even worse results
were obtained using the equation 2 with r2 from 0.642 to 0.803
and the error ranging from —40.23% to 79.64%.
Similar results were obtained by means of the equation 3: r2
ranged from 0.919 to 0.984 with a marked tendency to AUG
overestimation and a large error in prediction ranging from
—5.55% to 90.25%. The poorest results were obtained using
equation [4] even though markedly different from set to set of
data: r2 was 0.784 using RIA data of 56 pharmacokinetic profiles
(with error of predicted AUG varying from —24.05% to
130.71%) and increased to 0.953 with HPLC data (with error of
predicted AUG from —12.32% to 33.39%). When considering
pharmacokinetic profiles determined by HPLC and equation [5]
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Fig. 2. Percentage mean error and 95% confidence intervals in AUC prediction using different models. Key: (A) single time point equation and
(B) three time points equation developed using our own data; (C) three time points equation developed using our own RIA data applied to HPLC
data; (D) Johnston et al equation (time points: 3, 8, and 10 hr); (F) Johnston et al equation (time points: 4, 8, and 10 hr); (F) Johnston et al equation
(single time point); (G) Grevel and Kahan equation; and (H) Meyer et at equation.
derived from our RIA data, the correlation between predicted
and measured AUC was good (r2 0.989) but the error in
prediction of AUC ranged from —14.3 1% to 50.24%.
Overall the equations proposed by Johnston et ailed to an
average underestimation of AUC, while the models by Grevel
and Kahan and by Meyer et al resulted in a marked overesti-
mation. This might be explained by the large differences in the
coefficient of determination between single time points and
AUC values observed by the various investigators. Thus the
highest coefficient of determination was found at five hours (r2
= 0.894) [6], 24 hours (r2 = 0.820) [7], and six hours (r2 = 0.941)
[4], compared with 12 hours (r2 = 0.830) for our data.
The performance of the above equations was also tested by
calculating the 95% confidence intervals for each set of data.
The results of this analysis are depicted in Figure 2. When
analyzing RIA data from 56 pharmacokinetic profiles, only the
equation derived from our data (eq. 5) and the model which
used a single time point (eq. 2) gave a zero error value was
inside the 95% confidence interval; however, in both cases the
range in error prediction was very large.
With RIA data from the subset of 33 patients, the zero error
value was inside the 95% confidence interval when using the
single time point equation derived from our data for AUC
prediction, and again with equation 2. In both cases the error in
prediction was extremely large.
HPLC blood concentrations resulted in zero error inside the
95% confidence interval in three instances, namely when pre-
dicting AUC with equation 1 and with equations based either on
one or three time points derived from our own data. However,
only in the last case the error in prediction was relatively small
(—15.98% to 15.62%). Thus, even when the mean prediction
error was not statistically different from zero (Fig. 2), individual
values showed a very large prediction error making unaccept-
able the proposed models for AUC prediction.
A possible explanation of the poor results we obtained could
be due to the analytical method of CsA determination. Indeed,
the polyclonal antibody of the RIA cross reacts with many of
the metabolites of CsA and therefore is unable to differentiate
between the parent compound and its metabolites, the latter
being of no utility in pharmacokinetic prediction [1—3]. How-
ever, the CsA levels we considered were always determined by
using an RIA assay with a specific monoclonal antibody which
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leads to only a moderate overestimation of CsA concentration
(in our laboratory HPLC and RIA are almost equivalent with a
close correlation between the methods: RIA = 1.17 x HPLC +
18, r = 0.972). On the other hand, in the present study AUC
predictions performed with data obtained by HPLC, which
measures only CsA, were still unacceptable, even though the
associated error was lower than with RIA data.
We conclude that a limited sampling strategy used to monitor
CsA blood levels does not adequately reflect the AUC but tends
to lead either to major over- or underestimation of the real AUC
values.
Reprint requests to Flavio Gaspari, Chem. D. • Mario Negri Institute
for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo,
Italy.
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